October 18th 2024
The FREEDOM2 study demonstrates that fedratinib is an effective second-line treatment for myelofibrosis after ruxolitinib failure or intolerance.
September 30th 2024
September 13th 2024
September 12th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Data Supports Pacritinib Efficacy in Myelofibrosis
December 12th 2016Findings of a recent randomized trial showed patients with myelofibrosis and thrombocytopenia had significantly greater reductions in spleen volume and symptoms when treated with the multikinase inhibitor pacritinib, compared with the best available therapy (BAT).
Read More
Ropeginterferon as Effective but Safer Than Hydroxyurea in Polycythemia Vera
December 7th 2016Ropeginterferon alfa-2b is noninferior to hydroxyurea in terms of complete hematologic response for the treatment of polycythemia vera, and has the advantage of being a safer and more tolerable therapy.
Read More
Evolving NCCN Guidelines for MPNs
November 10th 2016Ruben A. Mesa, MD, chair, Division of Hematology and Medical Oncology, deputy director, professor of Medicine, Mayo Clinic, discusses the NCCN Clinical Practice Guidelines for myeloproliferative neoplasms (MPNs) and who the recommendations will transition over the next year. Mesa spoke on the topic during an interview at the 34th Annual Chemotherapy Foundation Symposium™, held November 9-11, 2016 in New York City.
Watch